Lung Cancer Research Review, Issue 61

In this issue:

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA NSCLC
Single- vs. multifraction SABR for pulmonary oligometastases
Adding ramucirumab to second-line gemcitabine in malignant pleural mesothelioma
SABR for operable stage I NSCLC
Savolitinib for METex14 pulmonary sarcomatoid carcinomas and other NSCLCs
Hippocampal-avoiding prophylactic cranial irradiation in SCLC
Ramucirumab + erlotinib in metastatic NSCLC: EGFR mutation subgroup analysis
Antibiotic exposure does not impact NSCLC outcomes after first-line chemoimmunotherapy
Glasgow prognostic score predicts survival in high PD-L1 NSCLC after first-line pembrolizumab
Pembrolizumab + platinum-based chemotherapy in NSCLC with stable brain metastases

Please login below to download this issue (PDF)

Subscribe